The low BRCA1 positive rate in our cohort was attributed to the geographical differences in the enrollment cohort and the high-grade serous carcinoma in the other study population, suggesting that the deleterious mutations of BRCA1 were associated with a greater incidence of malignant ovarian cancer. The gene discussed is BRCA1; the disease is serous adenocarcinoma.